Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2018

01-10-2018 | Review Paper

Orphan Nuclear Receptors in Colorectal Cancer

Authors: Michael E. Kelly, Helen M. Mohan, Alan W. Baird, Elizabeth J. Ryan, Des C. Winter

Published in: Pathology & Oncology Research | Issue 4/2018

Login to get access

Abstract

Colorectal cancer is one of the most common cancers worldwide, with an overall increased incidence annually. Despite improvements in treatment and surveillance, almost 50% develop recurrent and/or distant disease. Unknown cellular processes are the fundamental cause for treatment failure and metastatic disease. The interplay of chronic inflammation and carcinogenesis is well established. Recent work has highlighted the role of nuclear receptors and co-regulators in the inflammation to carcinogenesis process. Orphan nuclear receptors have been shown to be involved in numerous cellular processes, including both at a transcriptional and a non-genomic level. There is a significant emphasis to identify ligands that will interact and modify these nuclear receptors, with the long-term aim of developing novel pharmaceutical therapies. The identification of orphan nuclear receptor ligands will also help increase our current understanding of their role in cellular signaling, by enabling manipulation of these receptors. This review aims to provide a brief overview of some key orphan nuclear receptors which may be involved in colorectal cancer.
Literature
1.
2.
Rizzo A, Pallone F, Monteleone G, Fantini MC (2011) Intestinal inflammation and colorectal cancer: a double edged sword? World J Gastroenterol 17:3092–3100PubMedPubMedCentral
3.
Riggins RB, Mazzotta MM, Maniya OZ, Clarke R (2010) Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer 17(3):213–231CrossRef
4.
5.
6.
Lee JS, Kim KI, Baek SH (2008) Nuclear receptors and co-regulators in inflammation and cancer. Cancer Lett 267:189–196CrossRefPubMed
7.
Safe S, Kim K, Li X, Lee SO (2011) NR4A orphan receptors and cancer. Nucl Recept Signal 9:1–14
8.
Evans RM (2005) The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19:1429–1438CrossRefPubMed
9.
Novac N, Heinzel T (2004) Nuclear receptors: overview and classification. Curr Drug Targets Inflamm Allergy 3:335–346CrossRefPubMed
10.
Robinson-Rechavi M, Garcia HE, Laudet V (2003) The nuclear receptor superfamily. J Cell Sci 116:585–586CrossRefPubMed
11.
Zhao Y, Bruemmer D (2010) NR4A Orphan Nuclear Receptors: Transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol 30(8):1535–1541CrossRefPubMedPubMedCentral
12.
Benoit G, Malewicz M, Perlmann T (2009) Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell Biol Chem 284:23286–23292
13.
Gallastegui N, Mackinnon JA, Fletterick RJ, Estébanez-Perpiñá E (2015) Advances in our structural understanding of orphan nuclear receptors.Trends Biochem Sci 2015;40(1):25–35
14.
Wu H, Lin Y, LI W, Sun Z, Gao W, Zhang H, Xie L, Jiang F, Qin B, Yan T, Chen L, Zhao Y, Cao X, Wu Y, Lin B, Zhou H, Wong AS, Zhang XK, Zeng JZ (2010) Regulation of Nurr 77 expression by beta-catenin and its mitogenic effect on colon cancer cells. FASEB J 25:192–205CrossRefPubMed
15.
16.
Giguere V, Yang N, Segui P, Evans RM (1988) Identification of new class of steroid hormone receptor. Nature 331:91–94CrossRefPubMed
17.
Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789–799CrossRefPubMed
18.
19.
Freedman LP, Luisi BF, Korszun ZR, Basavappa R, Sigler PB, Yamamoto KR (1988) The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature 334:543–546CrossRefPubMed
20.
21.
Blumberg B, Evans RM (1998) Orphan nuclear receptors – new ligands and new possibilities. Genes Dev 12:3149–3155CrossRefPubMed
22.
Ordentlich P (2003) Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr 1. J Biol Chem 278:24791–24799CrossRefPubMed
23.
Enmark E, Gustafsson JA (1996) Orphan nuclear receptors – the first eight years. Mol Endocrinol 10:1293–1307PubMed
24.
Boute N et al (2002) The use of resonance energy transfer in high-throughput screening. BRET versus FRET. Trend Pharmacol 23:351–354CrossRef
25.
Xu HE et al (2002) Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415:813–817CrossRefPubMed
26.
Mohan HM, Aherne CM, Rogers AC, Baird AW, Winter DC, Murphy EP (2012) Molecular pathways: The role of NR4A Orphan Nuclear Receptors in Cancer. Clin Cancer Res 18:3223–3228CrossRefPubMed
27.
28.
Martinez-Gonzalez J, Badimon L (2005) The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc Res 65:609–618CrossRefPubMed
29.
30.
Collins D, Hogan AM, Winter DC (2011) Microbial and viral pathogens in colorectal cancer. Lancet Oncol 12(5):504–512CrossRefPubMed
31.
Hogan AM, Kennelly R, Collins D et al (2009) Oestrogen inhibits human colonic motility by a non-genomic cell membrane receptor-dependent mechanism. Br J Surg 96(7):817–822CrossRefPubMed
32.
McMorrow JP, Murphy EP (2011) Inflammation: a role for NR4A orphan nuclear receptors? Biochem Soc Trans 39(2):688–693CrossRefPubMed
33.
Holla VR, Wu H, Shi Q, Menter DG, Dubois RN (2011) Nuclear orphan receptor NR4A2; Modulates fatty acid oxidation pathways in colorectal cancer. J Biol Chem 286(34):30003–30009CrossRefPubMedPubMedCentral
34.
Han Y, Cai H, Ma L, Ding Y, Tan X, Liu Y, Su T, Yu Y, Chang W, Zhang H, Fu C, Cao G Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received post-operative chemotherapy. Eur. J. Cancer. 2013; Jun 25. pii: S0959–8049(13)00461–9
35.
Li X, Tai HH (2009) Activation of thromboxane A2 receptors induces orphan nuclear receptors Nurr 1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis 30:1606–1613CrossRefPubMed
36.
Holla VR, Mann JR, Shi Q, Dubois RN (2006) Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 281(5):2676–2268CrossRefPubMed
37.
Palorini R, De Rasmo D, Gaviraghi M, Danna LS, Signorile A, Cirulli C, Chiaradonna F, Alberghina L, Papa S. Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration. Oncogene 2012; 32(3):352–362
38.
Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, Iuliano F, Acquaviva AM (2007) PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependant kinase A activation. Am J Physiol Gastrointest Liver Physiol 293:673–681CrossRef
39.
Zagani R, Hamzaoui N, Cacheux W, de Reynies A, Terris B, Chaussade S, Romagnolo B, Perret C, Lamarque D (2009) Cyclooxygenase-2 inhibitors down-regulate osteopontin and NR4A2 new therapeutic targets for colorectal cancers. Gastroenterology 137:1358–1366CrossRefPubMed
40.
Takamoto N, You LR, Moses K, Chiang C, Zimmer WE, Schwartz RJ, DeMayo FJ, Tsai MJ, Tsai SY (2005) COUP-TFII is essential for radial and anteroposterior patterning of the stomach. Development 132:2179–2189CrossRefPubMed
41.
42.
Liang R, Lin Y, Yuan CL, Liu ZH, Li YQ, Luo XL, Ye JZ, Ye HH (2018) High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer. Oncol Lett 15(4):5933–5939
43.
Xiao L, Wang J, Li J, Chen X, Xu P, Sun S, He D, Cong Y, Zhai Y (2015) RORα inhibits adipocyte-conditioned medium-induced colorectal cancer cell proliferation and migration and chick embryo chorioallantoic membrane angiopoiesis. Am J Physiol Cell Physiol. 308(5):C385–96
44.
Berman AY, Manna S, Schwartz NS, Katz YE, Sun Y, Behrmann CA, Yu JJ, Plas DR, Alayev A, Holz MK (2017) ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal Transduct Target Ther 2:e17035
45.
Shin D, Kim IS, Lee JM, Shin SY, Lee JH, Baek SH, Cho KH (2014) The hidden switches underlying RORα-mediated circuits that critically regulate uncontrolled cell proliferation. J Mol Cell Biol 6(4):338–348
46.
Wen Z, Pan T, Yang S, Liu J, Tao H, Zhao Y, Xu D, Shao W, Wu J, Liu X, Wang Y, Mao J, Zhu Y (2017) Up-regulated NRIP2 in colorectal cancer initiating cells modulates the Wnt pathway by targeting RORβ. Mol Cancer 16(1):20
47.
Wang C, Zhou Y, Ruan R, Zheng M, Han W, Liao L (2015) High expression of COUP-TF II cooperated with negative Smad4 expression predicts poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol 8(6):7112–7121
Metadata
Title
Orphan Nuclear Receptors in Colorectal Cancer
Authors
Michael E. Kelly
Helen M. Mohan
Alan W. Baird
Elizabeth J. Ryan
Des C. Winter
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0440-6

Other articles of this Issue 4/2018

Pathology & Oncology Research 4/2018 Go to the issue

Short Communication

The Impact of Routine Frozen Section Assessment During Penectomy on Surgical Margin Status and Long-Term Oncologic Outcomes

Original Article

Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma

Original Article

Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment

Short Communication

Stain-free Histopathology of Basal Cell Carcinoma by Dual Vibration Resonance Frequency CARS Microscopy

Original Article

MiR-184 Retarded the Proliferation, Invasiveness and Migration of Glioblastoma Cells by Repressing Stanniocalcin-2

Review

The ER – Glycogen Particle – Phagophore Triangle: A Hub Connecting Glycogenolysis and Glycophagy?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits